Skip to main content

Enliven Therapeutics, Inc.

corporate_fare Company Profile

Enliven Therapeutics, Inc.

ELVN·NASDAQ·Life Sciences·CIK 0001672619

We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics. Our goal is to improve survival and overall well-being by addressing unmet medical needs through a precision medicine approach. We combine insights into clinically validated biological targets with differentiated chemistry to design therapies. Our development process involves validated targets, which are those with demonstrated roles in disease pathology, along with specific target product profiles, disciplined clinical trial design, and regulatory strategy. We are currently developing ELVN-001 and pursuing additional research-stage opportunities. ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to target the breakpoint cluster region - Abelson ("BCR-ABL") gene fusion, which drives chronic myeloid leukemia ("CML"). It is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI) that blocks phosphorylation and oncogenic signaling by competing with ATP for binding at the kinase active site. While BCR-ABL TKIs have transformed CML prognosis, patients still face challenges such as primary or secondary resistance to existing TKIs, off-target activity of ATP-competitive TKIs (e.g., nilotinib, dasatinib) leading to adverse events, drug-drug interactions, and adherence difficulties due to specific food requirements for most BCR-ABL TKIs.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ELVN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ELVN spans 10-Q, 8-K, SCHEDULE 13D/A, 144.

Recent high-impact activity:

  • Enliven 10-Q: Q3 Loss Widens to $27.7M, $884.4M Cash Funds Operations Into 2030
  • Enliven Posts Q3 Loss, $884M Cash and Runway Into 2030 Ahead of ENABLE-2 Launch
  • FDA Signs Off on Phase 3 Trial Design for Enliven's Relcobatinib in CML
  • OrbiMed Reduces Stake in Enliven Therapeutics by Over 1%
  • Institutional Investor OrbiMed Files Intent to Sell $38.3M in Enliven Therapeutics Stock

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$103.69M
Diluted EPS
-$1.83
Op. Cash Flow
-$70.3M
Free Cash Flow
-$70.46M
Operating Income
-$119.66M
Cash & Equivalents
$98.9M
Debt / Equity
0.00×
Shares Outstanding
59.44M sh
Source: 10-K · filed 2026-03-03 · accession 0001193125-26-088232

Short Interest & Short Volume

5.69 days to cover

FINRA reported short interest of 10,293,807 shares in ELVN as of the October 30, 2026 settlement, a 10.3% increase from the prior period — about 5.7 days to cover at its recent average daily volume. On November 20, 2026, 84.8% of ELVN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,293,807 shares as of October 30, 2026
Change vs prior period▲ 10.3%
Days to cover5.69 at avg daily volume of 1,808,745
Daily short volume (FINRA facilities)84.8% of 285,048 shares on November 20, 2026
5-day average short volume64.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for ELVN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.

1 recent capital raiseATM program

Offering Finalized and Upsized · Pricing Details

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$46.53
52-week range · as of 2026-11-05 $14.79 – $62.32
Market cap
$3.42B
Volume
933.6K (0.7× avg)
3-mo avg 1.4M
Live data · 2026-11-21 11:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ELVN - Latest Insights

ELVN
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.79
Real-time Price: $46.53 info
Change: +$1.74 (+4%) info
Market Cap: $3.424B info
ELVN
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $44.79
Real-time Price: $46.53 info
Change: +$1.74 (+4%) info
Market Cap: $3.424B info
ELVN
Oct 06, 2026, 11:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $42.39
Real-time Price: $46.53 info
Change: +$4.14 (+10%) info
Market Cap: $3.424B info
ELVN
Jun 24, 2026, 7:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $47.60
Real-time Price: $46.53 info
Change: -$1.07 (-2%) info
Market Cap: $3.424B info
ELVN
Jun 22, 2026, 8:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $45.37
Real-time Price: $46.53 info
Change: +$1.16 (+3%) info
Market Cap: $3.424B info
ELVN
Jun 15, 2026, 9:21 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $42.60
Real-time Price: $46.53 info
Change: +$3.93 (+9%) info
Market Cap: $3.424B info
ELVN
Jun 12, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $45.47
Real-time Price: $46.53 info
Change: +$1.06 (+2%) info
Market Cap: $3.424B info
ELVN
Jun 12, 2026, 4:53 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $45.47
Real-time Price: $46.53 info
Change: +$1.06 (+2%) info
Market Cap: $3.424B info
ELVN
Jun 12, 2026, 2:14 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $46.94
Real-time Price: $46.53 info
Change: -$0.405 (-0.86%) info
Market Cap: $3.424B info
ELVN
Jun 11, 2026, 10:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $39.94
Real-time Price: $46.53 info
Change: +$6.59 (+16%) info
Market Cap: $3.424B info
ELVN
Jun 11, 2026, 5:27 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $46.53 info
Change: +$7.03 (+18%) info
Market Cap: $3.424B info
ELVN
Jun 11, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $40.37
Real-time Price: $46.53 info
Change: +$6.16 (+15%) info
Market Cap: $3.424B info
ELVN
Jun 11, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $42.00
Real-time Price: $46.53 info
Change: +$4.53 (+11%) info
Market Cap: $3.424B info
ELVN
Jun 11, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $41.17
Real-time Price: $46.53 info
Change: +$5.36 (+13%) info
Market Cap: $3.424B info
ELVN
Jun 09, 2026, 5:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.80
Real-time Price: $46.53 info
Change: +$12.73 (+38%) info
Market Cap: $3.424B info
ELVN
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $40.29
Real-time Price: $46.53 info
Change: +$6.24 (+15%) info
Market Cap: $3.424B info
ELVN
May 07, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $40.29
Real-time Price: $46.53 info
Change: +$6.24 (+15%) info
Market Cap: $3.424B info
ELVN
Apr 15, 2026, 4:06 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $43.95
Real-time Price: $46.53 info
Change: +$2.58 (+6%) info
Market Cap: $3.424B info
ELVN
Mar 24, 2026, 4:26 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $31.15
Real-time Price: $46.53 info
Change: +$15.38 (+49%) info
Market Cap: $3.424B info
ELVN
Mar 03, 2026, 4:53 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $28.75
Real-time Price: $46.53 info
Change: +$17.78 (+62%) info
Market Cap: $3.424B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets